← All trials
NCT06585020
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2027
- First posted
- Sep 5, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Picardie Jules VerneLead sponsor
- Rouen Normandy UniversityCollaborator
- University of BordeauxCollaborator
- Central Hospital Saint QuentinCollaborator
- Croix-Rousse Hospital, LyonCollaborator
- University of ParisCollaborator
- University Hospital, ToursCollaborator
- University of RennesCollaborator
- CH PERPIGNANCollaborator
- University of StrasbourgCollaborator
- University of AngersCollaborator
- University of ReimsCollaborator
- University of GrenobleCollaborator
- Centre Hospitalier COMPIEGNECollaborator
- University of PoitiersCollaborator
- Centre Hospitalier le MansCollaborator
- Centre Hospitalier de CannesCollaborator
- Hospital AvicenneCollaborator
- University of Western BrittanyCollaborator
- University of BurgundyCollaborator
- Centre hospitalier de MulhouseCollaborator
- Centre hospitalier de PerpignanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.